Tredje AP fonden Invests $23.19 Million in Amgen Inc. $AMGN

Tredje AP fonden bought a new position in Amgen Inc. (NASDAQ:AMGN) during the fourth quarter, Holdings Channel reports. The fund bought 70,856 shares of the medical research company’s stock, valued at approximately $23,192,000.

A number of other institutional investors and hedge funds also recently modified their holdings of AMGN. Dogwood Wealth Management LLC boosted its position in shares of Amgen by 275.0% in the 4th quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 55 shares during the period. Anfield Capital Management LLC raised its holdings in Amgen by 1,000.0% during the 4th quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock worth $25,000 after buying an additional 70 shares during the period. Board of the Pension Protection Fund purchased a new stake in Amgen during the fourth quarter valued at about $26,000. Manning & Napier Advisors LLC boosted its holdings in shares of Amgen by 49.2% in the fourth quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock worth $32,000 after buying an additional 32 shares during the period. Finally, Olistico Wealth LLC acquired a new position in shares of Amgen in the fourth quarter worth about $33,000. 76.50% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

AMGN has been the topic of a number of recent analyst reports. Argus boosted their price target on shares of Amgen from $360.00 to $400.00 and gave the company a “buy” rating in a report on Friday, February 6th. Barclays began coverage on shares of Amgen in a research note on Friday, February 20th. They issued an “equal weight” rating and a $350.00 price objective for the company. Mizuho lifted their price objective on shares of Amgen from $280.00 to $295.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 10th. Citigroup boosted their target price on shares of Amgen from $315.00 to $345.00 and gave the company a “neutral” rating in a research note on Wednesday, February 4th. Finally, Sanford C. Bernstein downgraded shares of Amgen from an “outperform” rating to a “market perform” rating and set a $335.00 target price on the stock. in a research note on Tuesday, January 20th. Two analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, fourteen have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Amgen has a consensus rating of “Hold” and an average price target of $356.15.

Amgen Stock Performance

Shares of AMGN opened at $324.39 on Tuesday. The company has a market capitalization of $175.07 billion, a PE ratio of 22.57, a PEG ratio of 3.28 and a beta of 0.44. The company has a debt-to-equity ratio of 5.65, a quick ratio of 1.01 and a current ratio of 1.26. The company’s 50 day moving average price is $348.31 and its 200 day moving average price is $343.59. Amgen Inc. has a 52 week low of $267.83 and a 52 week high of $391.29.

Amgen (NASDAQ:AMGN) last released its earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.77 by $0.38. The company had revenue of $8.62 billion during the quarter, compared to the consensus estimate of $8.58 billion. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The company’s revenue was up 5.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $4.90 EPS. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Research analysts expect that Amgen Inc. will post 22.37 EPS for the current fiscal year.

Amgen Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be issued a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a dividend yield of 3.1%. The ex-dividend date is Friday, May 15th. Amgen’s dividend payout ratio (DPR) is currently 70.15%.

Insider Transactions at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of the business’s stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $323.73, for a total value of $400,454.01. Following the transaction, the senior vice president owned 7,009 shares in the company, valued at $2,269,023.57. The trade was a 15.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 0.85% of the company’s stock.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.